Abstract: Objective To explore the application value of high flux hemodialysis(HFHD) in uremic elders. Methods From October 2018 to January 2020, a total of 102 uremic elders aged over 70 years were selected and randomized into two groups of study and control(n=51 each). On the basis of routine intervention, study group received 12-week HFHD while control group had 12-week low flux hemodialysis(LFHD). Clinical efficacy, blood urea nitrogen(BUN), serum creatinine(Scr), p-cresol sulfate(PCS), indolyl sulfate(IS) and serum creatinine(Scr) of two groups were statistically analyzed. And β2-microglobulin(β2-mg), parathyroid hormone(PTH), neutrophil(NE) phagocytic function(phagocytic rate/index), serum inflammatory factors such as C-reactive protein(CRP), tumor necrosis factor-α(TNF-α), interleukin-6(IL-6) and interleukin-8(IL-8) were measured. The parameters of calcium and phosphorus metabolism, such as serum calcium(CA) and phosphorus(P), were followed up for 3 months. Results The overall effective rate of study group was higher than that of control group(94. 12% vs 80. 39%) (P<0. 05). At 6 and 12 weeks of treatment, serum BUN, Scr, PCs, IS, β2-MG, PTH, CRP and TNF-α declined and their levels were lower than controls. The levels of IL-6, IL-8 and P were lower in study group than those in control group(P<0. 05);At 6 and 12 weeks of treatment, NE phagocytosis rate/index of two groups were higher than pre-treatment and study group was higher than control group(P<0. 05);no significant inter-group difference existed in mortality at Month 1/2/3 post-treatment(P>0. 05). Conclusion HFHD technology can effectively improve the therapeutic efficacy for uremic elders. It is probably correlated to a more effective removal of toxins, a modulation of serum inflammatory factors, calcium and phosphorus metabolism and NE phagocytosis.